Brandon Capital
by
1M ago
Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease Melbourne, Australia and London UK, 10 October 2023 – Brandon Capital, an international venture capital firm and Australasia’s leading early-stage life science investor, is pleased to announce its investment into AstronauTx Ltd, a UK-based biotech company developing ..read more
Visit website
CUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Brandon Capital
by
2M ago
Expressions of Interest for CUREator+, a newly created $50 million program by Brandon BioCatalyst and ANDHealth, are now open. Selected by the Federal Government’s Medical Research Future Fund (MRFF) through a competitive process, Brandon BioCatalyst in partnership with ANDHealth will deliver the incubator program to startup companies with commercial potential. CUREator+ will provide successful startup ..read more
Visit website
Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer
Brandon Capital
by
6M ago
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform technology, today announced the appointment of Dr. Rochelle Chaiken, as Chief Medical Officer. Dr. Chaiken joins Vaxxas following a 23-year career at Pfizer, bringing extensive experience designing and executing late-stage clinical trials and successfully launching new products in markets. Reporting to Vaxxas Chief Executive Officer ..read more
Visit website
Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity
Brandon Capital
by
6M ago
BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate, GLY-200, for the treatment of type 2 diabetes (T2D) and obesity. Data across completed Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of GLY-200 offers ..read more
Visit website
Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Brandon Capital
by
6M ago
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology. The COVID-19 vaccine patch is based upon HD-MAP delivery of a SARS-CoV-2 spike subunit vaccine candidate from The ..read more
Visit website
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
Brandon Capital
by
6M ago
Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. These results support the further clinical development of INNA-051 to mitigate the impact of natural infection by respiratory viruses such as SARS-CoV-2 and its variants: influenza, RSV, and the common cold, in ..read more
Visit website
Tech entrepreneur amongst stellar cohort in latest Women in Leadership Development (WILD) Program, which is expanding with new Federal investment
Brandon Capital
by
6M ago
The WILD Women team, supported by Brandon BioCatalyst, receives further funding to expand successful Science, Technology, Engineering and Mathematics (STEM) women’s leadership program. Women represent 27 per cent of the STEM workforce but hold just 8 per cent of CEO roles, less than the 20 per cent figure across the broader economy – Workplace Gender ..read more
Visit website
EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation
Brandon Capital
by
6M ago
EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System. EBR Systems’ WiSE CRT System is on track for the Premarket Approval (PMA) application to the Food and Drug Administration ..read more
Visit website
Brandon BioCatalyst, in partnership with ANDHealth, selected by the Federal Government to deliver $50m BioMedTech Incubator Program
Brandon Capital
by
6M ago
Federal investment creates a combined funding capability of $115m across programs managed by Brandon BioCatalyst & ANDHealth. Brandon BioCatalyst, in partnership with ANDHealth, has been selected by the Federal Government to deliver the $50m BioMedTech Incubator (BMTI) program. The investment, from the $20b Medical Research Future fund (MRFF), substantially increases the grant funding available through existing Brandon ..read more
Visit website
Nineteen groundbreaking biotech projects selected for national incubator
Brandon Capital
by
6M ago
CUREator, Australia’s national biotech incubator, today announces its second round of funding, awarding $12 million to 19 projects targeting global health challenges   including advances in treatment for lupus, motor neurone disease, brain and ovarian cancer, and inflammatory bowel disease. CUREator is delivered through an initial $40m in funding from the Federal Government’s Medical Research Future ..read more
Visit website

Follow Brandon Capital on FeedSpot

Continue with Google
Continue with Apple
OR